Intravitreal Bevacizumab Vs Photocoagulation for Proliferative Diabetic Retinopathy

• Status: Unknown status
• Trial end date: 2007-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the safety and efficacy of 2.5 mg of intravitreal bevacizumab in one eye, versus panretinal photocoagulation in the contralateral eye, for the treatment of patients with untreated symmetric proliferative diabetic retinopathy.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asociación para Evitar la Ceguera en México
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• symmetric proliferative diabetic retinopathy without high risk characteristics

• age 18 years or older

• patient consent

Exclusion Criteria:

• heart attack or cerebrovascular attack

• only eye

• retinal detachment

• vitreous haemorrhage

• previous treatment for diabetic retinopathy

• media opacities that preclude visualization of the fundus

• pregnancy

• inability to understands the implications of the protocol